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.2012.10.0Abstract Staphylococcus aureus and Pseudomonas aeruginosa are rapidly increasing as multidrug
resistant strains worldwide. In nosocomial settings because of heavy exposure of different antimicro-
bials, resistance in these pathogens turned into a grave issue in both developed and developing
countries. The aim of this study was to investigate in vitro antibiotic synergism of combinations of
b-lactam–b-lactam and b-lactam–aminoglycoside against clinical isolates of S. aureus and
P. aeruginosa. Synergy was determined by checkerboard double dilution method. The combination
of amoxicillin and cefadroxil was found to be synergistic against 47 S. aureus isolates, in the FICI
range of 0.14–0.50 (81.03%) followed by the combination of streptomycin and cefadroxil synergistic
against 44 S. aureus isolates in the FICI range of 0.03–0.50 (75.86%). The combination of streptomy-
cin and cefadroxil was observed to be synergistic against 39P. aeruginosa isolates in the FICI range of
0.16–0.50 (81.28%). Further actions are needed to characterize the possible interaction mechanism
between these antibiotics. Moreover, the combination of streptomycin and cefadroxil may lead to
the development of a new and vital antimicrobial against simultaneous infections of S. aureus and
P. aeruginosa.
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051. Introduction
The current clinical scenario indicates that millions of people
are becoming infected with nosocomial infection leading to
numerous deaths annually worldwide and to heavy economic
burden in both developed and developing countries (WHO,
2002). Emerging trends in nosocomial infections signal high
alerts towards multidrug resistant pathogens. Studies show
that 70% of nosocomial infections are due to antibiotic
resistant strains (Burke, 2003; Safdar et al., 2001). Major
causative agents include antibiotic resistant strains of
Staphylococcus aureus and Pseudomonas aeruginosa. Both of
these organisms are among the most common isolates from
burnt patients especially under nosocomial conditions (Haghi
et al., 2010).vier B.V. All rights reserved.
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80 Z. Ahmed et al.In an increasing number of microbial infections of man,
treatment with single antibiotic fails to cure. Some of these
infections, however, respond favourably to combined treat-
ment with two antibiotic drugs. Certain pairs of these drugs
have proved successful in a limited number of clinical
situations. The clinical signiﬁcance of in vitro synergism has
not yet been deﬁned in the treatment of many infections. There-
fore, this study was undertaken to investigate the effectiveness
of combinations of antibiotics against clinical isolates of S. aur-
eus and P. aeruginosa which are synergistic in vitro. It will be
shown that the use of two antibiotics that are synergistic
in vitro against the microorganism responsible for the infection
may be associated with a signiﬁcantly better outcome than that
achieved with a combination which is not synergistic for the
offending microorganism. Synergistic activity of antimicrobials
cannot be assumed and should be tested for, prior to commenc-
ing treatment with a combination regimen (Prinsloo et al.,
2008). Therefore this study was aimed to assess the in vitro syn-
ergy of three antibiotics against 58 clinical isolates of S. aureus
and 48 clinical isolates of P. aeruginosa. The manuscript does
not contain experiments using animals and human studies.a
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.2. Material and methods
2.1. S. aureus and P. aeruginosa isolates
A total of 58 S. aureus and 48 P. aeruginosa isolates included in
the present study were taken from the collection of the Visha-
kha Clinical Microbiology Laboratory, Nagpur, India. The
clinical isolates were from different specimens like pus, swab,
sputum, blood and wound discharge of patients attending
the health centres of Nagpur district. Their species identity
was conﬁrmed by biochemical tests including catalase, coagu-
lase, and by growth characteristics on Mannitol salt agar for S.
aureus, and Glucose utilization, Indole, MR (Methyl red), VP
(Voges-Proskauer), Catalase, Oxidase, and by growth charac-
teristics on Cetrimide agar for P. aeruginosa.
2.2. Antimicrobial agents
Antimicrobial agents, namely amoxicillin and streptomycin
were procured from Himedia Laboratories Pvt. Ltd., Mumbai,
India, cefadroxil was procured from IFPRESS, Mumbai, India
and ampicillin (Roscillin) was procured from Ranbaxy. All
drugs were dissolved in their respective solvents and diluted
in deionized water and ﬁltered through 0.22 l Millipore ﬁlter.
Drug stocks were stored at 20 C.
2.3. Susceptibility test
Antibiotics susceptibility test was done for all isolates of S.
aureus and P. aeruginosa, using Kirby-Bauer disc diffusion
method (Bauer et al., 1966). Antibiotic discs were obtained
from Himedia Laboratories Pvt. Ltd., Mumbai including
amoxicillin (10 lg), ampicillin (10 lg), streptomycin (10 lg)
and cefadroxil (30 lg). The diameters of the zones of inhibition
were interpreted in Tables 2A through 2I (Zone Diameter
Interpretative Standards and equivalent Minimum Inhibitory
Concentration Breakpoints) of the NCCLS M100-S12T A te A A S
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resistant to the agents that have been tested.
2.4. MIC and FICI determination
In vitro checkerboard studies on the activity of antibiotics
alone and in combination were performed in Muller Hinton
broth (Himedia Ltd.) in tube dilution. Twofold dilutions
(0.125–256 lg ml1) of each drug or drug combination were
tested in two rows. One row was inoculated with 105 organ-
isms/ml of the test organism and the second row was inocu-
lated with the control organism. Results were read after
tubes were incubated at 37 ± 2 C for 18 h. MIC (Minimum
inhibitory concentration) is determined as the lowest concen-
tration of the drugs (alone or in combination) that inhibit
growth. The fractional inhibitory concentration index (FICI)
is deﬁned as the sum of the MIC of each drug when used in
combination divided by the MIC of the drug used alone.
Synergistic effect was recorded when FIC indexes 60.5; partial
synergy when FIC >0.5 but <1.0; additive when FIC = 1.0;
indifferent when FIC >1.0 but <4.0 and antagonistic when
FIC P4.0 (Cai et al., 2007).
3. Results
The in vitro results of interaction of cefadroxil with amoxicil-
lin, ampicillin and streptomycin are presented in Table 1. Disc
diffusion test results showed that about 90% S. aureus isolates
were resistant to amoxicillin and ampicillin, however both of
these antibiotics were found to be ineffective against all
P. aeruginosa isolates (100% resistance). About 33% and
36% S. aureus isolates and about 29% and 23% P. aeruginosa
isolates were susceptible to cefadroxil and streptomycin
respectively.
The results of checkerboard analysis illustrated (Table 1)
that the combination of cefadroxil and amoxicillin was most
effective against S. aureus isolates with 81.03% (47) synergism
(FIC index 0.14–0.50) and less than 10% of other effects. FIC
value distribution among 58 S. aureus isolates is presented in
Fig. 1. The same combination of antibiotics found to be mar-
ginally synergistic i.e. 14.58% (7) (FIC index 0.09–0.38) butN
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Figure 1 FICI of antibiotic combinations against S. aureus
isolates.F
ishigher side towards partial synergism 47.92% (23) (FIC index
0.52–0.75) and indifference 27.08% (13) (FIC index 1.06–2.06),
is presented in Fig. 2.
FIC index interpretation for activities of cefadroxil with
ampicillin against S. aureus isolates predominantly showed
indifference 41.38% (24) (FIC index 1.03–2.5) and same com-
bination of antibiotics against P. aeruginosa isolates predomi-
nantly showed partial synergism 39.58% (19) (FIC index 0.52–
0.75).
Cefadroxil combined with streptomycin produced predom-
inant synergism 75.86% (44) (FIC index 0.03–0.50) against S.
aureus isolates and maximum synergism i.e. 81.28% (39) (FIC
index 0.16–0.50) against P. aeruginosa isolates with least other
effects.
No antagonism with any combination of antibiotics was
observed in the present study.
4. Discussion
Infections caused by S. aureus and P. aeruginosa are increasing
both in hospitals and in general community (Hauser and Sri-
ram, 2005; Maltezou and Giamarellou, 2006). The efﬁcacy of
many antibiotics for treatment of severe infections has become
quite limited due to the development of resistance. The results
from this in vitro study with 58 S. aureus clinical isolates for
their susceptibility against different antibiotics indicated
8.62% and 13.79% sensitivity to ampicillin and amoxicillin
respectively. Cefadroxil and streptomycin were found to be
effective against 32.76% and 36.21% isolates. Our results also
substantiate previous study of Adegoke and Komolafe (2009).
Penicillins and Cephalosporins are the b-lactam antibiotics
which inhibit cell wall synthesis. Resistance against these anti-
biotics revealed that the resistance is purely plasmid based
since b-lactamase production is plasmid based (Rigby, 1986).
Kondo et al. (1991) had reported good activities of streptomy-
cin (MIC 1.56–6.25 lg/ml) against all tested strains of MRSA.
The present study showed that 62.07% strains of S. aureus
were resistant to streptomycin.
The in vitro study with 48 clinical isolates of P. aeruginosa
exhibited various degrees of inhibition against different antibi-
otics. Total 100% resistance was observed against amoxicillin
82 Z. Ahmed et al.and ampicillin.Whereas, 70.83%and77.08%resistancewas ob-
served against cefadroxil and streptomycin respectively, earlier
studies also showed similar ﬁndings (Anjum and Mir, 2010).
The multidrug resistance among P. aeruginosa isolates may in-
volve reduced cell wall permeability, production of chromo-
somal and plasmid mediated b-lactamases (Livermore, 1989),
aminoglycoside-modifying enzymes (Livermore, 1987), and an
active multidrug efﬂux mechanism (Shahid and Malik, 2004).
The rational for combination therapy is essential to reduce
the chances of selection of resistant mutants during therapy, as
well as to exploit the potential synergistic activity of some
agents. We observed that the combination of cefadroxil and
amoxicillin (both are b-lactam drugs) was most synergistic
against S. aureus inhibiting more than 80% isolates. Previous
studies also illustrated synergism between two b-lactam antibi-
otics against different organisms (Gutmann et al., 1986; Pas-
ticci et al., 2008; Jones and Johnson, 1998; Matsumoto,
1998; Tascini et al., 2004; Desbiolles et al., 2001).
Against P. aeruginosa, the combination of cefadroxil and
streptomycin (b-lactam and aminoglycoside) was found to be
most effective, showed more than 80% inhibition. It was also
observed that this combination was also synergistic against
more than 75% isolates of S. aureus.
Gram-negative bacteria such as P. aeruginosa are often
simultaneously isolated from patients with MRSA infections
(Konno, 1995). Therefore, monotherapy with agents with
activities against gram-positive bacteria, such as vancomycin,
is not effective against polymicrobial infections caused by both
MRSA and P. aeruginosa (Shimizu et al., 1996). A better ap-
proach to the development of a new antibiotic combination
would be to aim for broad and potent activities against a wide
range of Gram-positive and Gram-negative bacteria including
S. aureus and P. aeruginosa. Our results demonstrated that the
combination of cefadroxil and streptomycin was synergistic
against both S. aureus and P. aeruginosa.
5. Conclusion
Our data clearly state that the use of synergistic combinations
for therapy of polymicrobial infections and infection of multi-
drug resistant strains is coupled with a better clinical response
than the use of nonsynergistic combinations. Each situation in
which it seems prudent or necessary to use antibiotics in combi-
nation must be carefully evaluated. The dangers of toxicity,
sensitization, superinfection, or increase in resistant organisms
that may follow the use of an additional antibiotic, should be
minimized. However, the mortality in severe nosocomial infec-
tions is extremely high, especially in debilitated patients, and the
use of synergistic combinations of antibiotics might prove to be
a valuable means for reducing this high mortality rate.
Therefore, when one is dealing with a serious infection presum-
ably caused by S. aureus and P. aeruginosa, it might be useful to
test routinely combinations of antibiotics for a potential syner-
gistic action. Routine use of combinations of antibiotics should,
however, be practiced with caution after prior in vitro trials.References
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